Healius Limited (ASX:HLS)
Australia
· Delayed Price · Currency is AUD | Market Cap | 373.96M |
| Revenue (ttm) | 1.37B |
| Net Income (ttm) | -168.80M |
| Shares Out | 726.13M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | 42.92 |
| Dividend | 0.41 (80.19%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 2,541,469 |
| Average Volume | 3,622,698 |
| Open | 0.530 |
| Previous Close | 0.535 |
| Day's Range | 0.515 - 0.535 |
| 52-Week Range | 0.490 - 1.635 |
| Beta | 0.38 |
| RSI | 43.46 |
| Earnings Date | Aug 9, 2026 |
About Healius
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ... [Read more]
Financial Performance
In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.
Financial StatementsNews
Healius Ltd (ASX:HLS) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Healius Ltd (ASX:HLS) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges
Healius Earnings Call Transcript: H1 2026
Revenue grew 3.8% to AUD 688.1 million in H1 FY26, with strong cost savings and digital transformation driving margin improvement. FY26 EBIT is expected to align with consensus at around AUD 48 million, with further benefits from cost initiatives and high-value segment growth anticipated.
Healius Transcript: AGM 2025
The AGM highlighted a strong year with the sale of Lumus Imaging, debt repayment, and a special dividend. Strategic focus remains on digital transformation, operational efficiency, and achieving high single-digit EBIT margins by FY 2027. All resolutions passed with strong shareholder support.
Healius Earnings Call Transcript: H2 2025
Revenue grew 5.7% to AUD 1.34 billion, with pathology up 6% and genomics up 34.7%. Labor costs are targeted to remain flat in FY 2026, with AUD 15–20 million in cost savings planned. High single-digit margins are targeted by June 2027.
Healius Transcript: Investor Day 2025
A simplified, digitally enabled business model is being implemented, targeting high single-digit EBIT margins by June 2027. Key initiatives include the sale of Lumus Imaging, aggressive cost reduction, and expansion of non-MBS revenue streams such as genomics, vet pathology, and clinical trials. Digital transformation and operational standardization underpin efficiency and growth.
Healius Earnings Call Transcript: H1 2025
Group revenue rose 10% year-over-year, driven by strong pathology and Lumus Imaging growth, though higher labor costs weighed on margins. The sale of Lumus Imaging for AUD 965 million will fund debt repayment and a likely special dividend, with further transformation and productivity gains targeted in 2H25.
Healius Transcript: AGM 2024
The meeting focused on the sale of Lumus Imaging, debt reduction, and a renewed pathology strategy. Shareholders will receive a special dividend post-sale, and the board addressed challenges in margins, government funding, and digital transformation.
Healius Earnings Call Transcript: H2 2024
Group revenue grew 6.1% to AUD 1.74 billion, with EBIT at the top end of guidance and strong segment growth in pathology, imaging, and Agilex. Transformation initiatives exceeded targets, and the Lumus Imaging sale is progressing. Margin and volume improvements continue into FY 2025.